199166-37-5

Basic information

• Product Name: L-Serine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-O-(phenylmethyl)-, 2-cyclohexyl 3-(phenylmethyl) ester
• CAS NO: 199166-37-5
• Molecular Formula: C34H45N3O9
• Molecular Weight: 639.746
• Mol File: 199166-37-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: L-Serine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-O-(phenylmethyl)-, 2-cyclohexyl 3-(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Serine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-O-(phenylmethyl)-, 2-cyclohexyl 3-(phenylmethyl) ester(199166-37-5)
• EPA Substance Registry System: L-Serine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-O-(phenylmethyl)-, 2-cyclohexyl 3-(phenylmethyl) ester(199166-37-5)

Safety Data

• Hazardous Substances Data: 199166-37-5(Hazardous Substances Data)

Upstream product

• 171519-62-3 Boc-Asp(OcHex)-Ser(Bzl)-OBzl 
• 69871-79-0 (S)-benzyl 3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)propanoate 
• 4530-20-5 BOC-glycine 
• 792169-28-9 (S)-3-Amino-N-((S)-2-benzyloxy-1-benzyloxycarbonyl-ethyl)-succinamic acid cyclohexyl ester 

Downstream Products

• 199166-39-7 Boc-Arg(Tos)-Gly-Asp(OcHex)-Ser(Bzl)-OBzl 
• 91037-65-9 H-Arg-Gly-Asp-Ser-OH 
• 788804-09-1 (S)-3-(2-Amino-acetylamino)-N-((S)-2-benzyloxy-1-benzyloxycarbonyl-ethyl)-succinamic acid cyclohexyl ester 

Relevant articles and documents

Dual-acting agents that possess free radical scavenging and antithrombotic activities: Design, synthesis, and evaluation of phenolic tetrahydro-β-carboline RGD peptide conjugates

A new approach to construct a single dual-acting agent is described. Compounds 6a-c are potent free radical scavengers as demonstrated by the EC50 values in PC12 cell survival assay in term of NO, H2O2, and {radical dot}OH scavenging activity. The Ach-induced vaso-relaxation assay further confirms the potent NO scavenging activity of compounds 6a-c. In addition, 6a-c are efficacious in a rat arterial thrombosis, and are active in ADP- or PAF-induced in vitro platelet aggregation assay, suggesting that compounds 6a-c also possess anti-thrombotic activities. Since both free radical and thrombogenesis are important risk factors in myocardial ischemic/reperfusion injuries, these dual-acting agents having both free radical scavenging and antithrombolic activities may potentially be beneficial toward their treatment.